Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
Recruiting · NCT05985850 · Registry updated 2025-02-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy | Chemically-Induced Disorders, Narcotic-Related Disorders, Neurologic Manifestations, Opioid Use Disorder, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cannabis dependence, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2025-02-17 | NCT05985850 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BC Centre on Substance Use | 2 |
| Canadian Institutes of Health Research (CIHR) | 339 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Rapid Access Addiction Clinic (RAAC), St. Paul's Hospital | Vancouver | Canada | 1 |